Snowden Capital Advisors’s Definium Therapeutics DFTX Stock Holding History

Snowden Capital Advisors’s Portfolio DFTX Stock Details DFTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-13	Closed	–	–	1657
2021 Q4	$0	Buy	+13	New	+$415	﹤0.01%	2094

Other funds holding DFTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DCI

Data Collective IV Palo Alto, California $55.9M AUM 49.14% 1-Year Est. Return

Busey Bank Urbana, Illinois $3.68B AUM 26.6% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Swiss National Bank Zurich, Switzerland $174B AUM 30.96% 1-Year Est. Return

Snowden Capital Advisors's DFTX Position: Q1 2022 in Review

Snowden Capital Advisors sold out of Definium Therapeutics (DFTX) in Q1 2022, closing a stake of 13 shares.

Snowden Capital Advisors first reported a position in DFTX in Q4 2021 and held it in 1 quarter. The position peaked at $0 in Q4 2021. 159 funds tracked by Wall St. Rank hold DFTX as of Q1 2022.

Snowden Capital Advisors reported no remaining Definium Therapeutics position as of Q1 2022 after selling out during the quarter.
Snowden Capital Advisors sold 13 Definium Therapeutics shares in Q1 2022.
Snowden Capital Advisors first reported a position in Definium Therapeutics in Q4 2021 and held it in 1 quarter.
Snowden Capital Advisors's Definium Therapeutics position peaked at $0 in Q4 2021.
159 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2022.

Based on Snowden Capital Advisors's 13F filing for Q1 2022, filed 16 May 2022.